PharmaTher Holdings Ltd. (PHRRF)
| Previous Close | 0.2200 |
| Open | 0.2075 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1907 - 0.2132 |
| 52 Week Range | 0.1400 - 0.9890 |
| Volume | |
| Avg. Volume | 527,935 |
| Market Cap | 14.346M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 6.70 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psilocybin pharmaceutical de
- GlobeNewswire
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine prescription-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted an investigator-initiated investigational new drug ("IND") application to proceed with a Phase 2 clinical trial (the “Study”) evaluating ketamine in the treatment of Amyotrophic Late
- GlobeNewswire
PharmaTher Announces Publication of Research Data for KETABET™
Second published study to demonstrate the potential therapeutic utility and mechanism of action of KETABET™ (patented combination of ketamine and betaine) in models of depression Repeated use of KETABET™ exhibits potential protective and reversing effects on ketamine-elicited psychotomimetic behaviors and cognitive impairments Supports clinical initiatives as a potential next generation ketamine treatment for mental health and pain disorders with patent protection into 2036 TORONTO, Jan. 04, 202
